secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001619856-24-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences reports FY 2023 net loss $102.1M, cash $372.4M; clinical updates
--------------------------------------------------------------------------------

- Net loss $102.1M in FY 2023 vs $99.4M in FY 2022; R&D expenses rose to $112.1M.
- Cash, equivalents, and marketable securities $372.4M at Dec 31, 2023, up from $317.0M; expected to fund operations into Q1 2026.
- CB-010: 30th patient dosed in ANTLER dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024.
- CB-012: First patient dosed in AMpLify Phase 1 trial for r/r AML.
- CB-020 preclinical anti-ROR1 CAR-NK program paused; CB-011 enrollment continues at dose level 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000012/0001619856-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000012/crbu-20240311.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer